We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Study: High-Dose Aspirin Behind US Efficacy Issues for AstraZeneca’s Brilinta
Study: High-Dose Aspirin Behind US Efficacy Issues for AstraZeneca’s Brilinta
June 29, 2011
A new study confirms suspicions that high-dose aspirin interferes with the efficacy of AstraZeneca’s potential blockbuster heart drug Brilinta.